Literature DB >> 2826345

Up- and down-regulation of human lymphokine (IL-2)-activated killer cell induction by monocytes, depending on their functional state.

A Nii1, S Sone, T Utsugi, H Yanagawa, T Ogura.   

Abstract

Studies were made to determine whether freshly isolated monocytes from healthy donors could influence the induction of lymphokine (IL-2)-activated killer (LAK) activity. Highly purified lymphocytes (greater than 99%) and monocytes (greater than 90%) were isolated by counter-flow centrifugal elutriation from peripheral blood. Lymphocytes incubated for 4 days with IL-2 showed significant LAK activity against natural killer (NK) cell-resistant target (Daudi) cells, whereas monocytes treated for 4 days with IL-2 and/or IFN-gamma were not cytotoxic. Under the experimental conditions used, addition of monocytes to the lymphocyte cultures resulted in significant augmentation of the LAK activity, depending on the density of monocytes added. In contrast, monocytes stimulated by lipopolysaccharide (LPS) markedly suppressed LAK activity induced by IL-2, depending on the dose of LPS added. Similar up- and down-regulations of LAK cell induction by monocytes were observed with 4 lines of human lung cancer cells as targets for LAK activity. Although supernatants from untreated monocytes did not increase LAK induction, supernatants from LPS-stimulated monocytes suppressed LAK induction. The regulatory role of monocytes could not be replaced by the addition of exogenous interleukin I (IL-I) or tumor necrosis factor (TNF). Prostaglandin E did not seem to play a regulatory role, since addition of indomethacin did not affect the regulation of LAK cell induction by monocytes. These results clearly indicate that human monocytes may cause up- or down-regulation of the expression of IL-2-induced LAK activity, depending on their functional state.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2826345     DOI: 10.1002/ijc.2910410108

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Human lymphokine-activated killer (LAK) cells. I. Depletion of monocytes from peripheral blood mononuclear cells by L-phenylalanine methyl ester: an optimization of LAK cell generation at high cell density.

Authors:  K H Leung
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.

Authors:  M Rodolfo; C Salvi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Induction of lymphokine-activated killer activity in rat splenocyte cultures: the importance of 2-mercaptoethanol and indomethacin.

Authors:  P J Kuppen; A M Eggermont; A Marinelli; E de Heer; C J van de Velde; G J Fleuren
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Soluble factors produced by macrophages/monocytes inhibit lymphokine-activated killer activity in rat splenocyte cultures.

Authors:  P J Kuppen; A M Eggermont; R B Quak; A Marinelli; C J van de Velde; G J Fleuren
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

5.  Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.

Authors:  M Toledano; C Mathiot; J Michon; G Andreu; D Lando; M Brandely; W H Fridman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Augmentation by transferrin of IL-2-inducible killer activity and perforin production of human CD8+ T cells.

Authors:  A Nakamura; S Sone; R Nabioullin; K Sugihara; M Munekata; Y Nishioka; A Nii; T Ogura
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

7.  Effects of tumour necrosis factor-alpha (TNF-alpha), IL-1 beta and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes.

Authors:  K Yoneda; T Osaki; T Yamamoto; E Ueta
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

8.  Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.

Authors:  K Yoneda; T Yamamoto; E Ueta; T Osaki
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

9.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) counteracts the inhibiting effect of monocytes on natural killer (NK) cells.

Authors:  G van den Bosch; F Preijers; A Vreugdenhil; J Hendriks; F Maas; T De Witte
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

10.  Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.

Authors:  P M Furbert-Harris; C H Evans
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.